Fate of Antibody-Drug Conjugates in Cancer Cells

Journal of Experimental and Clinical Cancer Research

Volumn 37, Issue 1, 2018, Pages

  Chalouni, Cécile ^a   Doll, Sophia ^b  

^a GENENTECH INC   (United States)

^b MAX PLANCK INSTITUTE   (Germany)

Author keywords

Antibody drug conjugates; Endocytic compartments; Endocytosis; Intracellular trafficking

Indexed keywords

ANTIBODY DRUG CONJUGATE; BIPARATOPIC ANTIBODY; BRENTUXIMAB VEDOTIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMTUZUMAB OZOGAMICIN; IMGN 779; PERTUZUMAB; SGN 33A; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; VADASTUXIMAB TALIRINE; ANTIBODY CONJUGATE; BIOLOGICAL MARKER; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CELL DEATH; CELL KILLING; CELL MIGRATION; CELL PROLIFERATION; CYTOTOXICITY; DRUG EFFICACY; DRUG TOLERABILITY; G2 PHASE CELL CYCLE CHECKPOINT; HODGKIN DISEASE; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER; INTERNALIZATION; MITOSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; ANIMAL; CHEMISTRY; ENDOCYTOSIS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM; PATHOLOGY; TISSUE DISTRIBUTION; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; BIOLOGICAL TRANSPORT; BIOMARKERS; ENDOCYTOSIS; HUMANS; IMMUNOCONJUGATES; METABOLIC NETWORKS AND PATHWAYS; MOLECULAR TARGETED THERAPY; NEOPLASMS; TISSUE DISTRIBUTION;

EID: 85041504278     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-017-0667-1     Document Type: Review

References (90)

1. Golay J, Introna M. Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays. Arch Biochem Biophys. 2012;526(2):146-53.
2. Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science. 2013;341(6151):1192-8.
3. Flygare JA, Pillow TH, Aristoff P. Antibody-drug conjugates for the treatment of cancer. Chem Biol Drug Des. 2013;81(1):113-21.
4. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov. 2006;5(2):147-59.
5. Teicher BA, Chari RV. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res. 2011;17(20):6389-97.
6. Erickson HK, et al. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther. 2012;11(5):1133-42.
7. Hughes B. Antibody-drug conjugates for cancer: poised to deliver? Nat Rev Drug Discov. 2010;9(9):665-7.
8. Doronina SO, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21(7):778-84.
9. Bouchard H, Viskov C, Garcia-Echeverria C. Antibody-drug conjugates-a new wave of cancer drugs. Bioorg Med Chem Lett. 2014;24(23):5357-63.
10. Oroudjev E, et al. Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol Cancer Ther. 2010;9(10):2700-13.
11. Jeffrey SC, et al. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug Chem. 2013;24(7):1256-63.
12. Prokop A, et al. Induction of apoptosis by enediyne antibiotic calicheamicin thetaII proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Bax-dependent manner. Oncogene. 2003;22(57):9107-20.
13. Nicolaou KC, et al. Synthetic calicheamicin mimics with novel initiation mechanisms: DNA cleavage, cytotoxicity, and apoptosis. Chem Biol. 1994;1(1):57-66.
14. Burris HA 3rd, et al. Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer. Clin Breast Cancer. 2011;11(5):275-82.
15. Coiffier B, et al. A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. Br J Haematol. 2016;173(5):722-30.
16. Rowe JM, Lowenberg B. Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood. 2013;121(24):4838-41.
17. Kung Sutherland MS, et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013;122(8):1455-63.
18. Goldenberg DM, et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015;6(26):22496-512.
19. Shen BQ, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol. 2012;30(2):184-9.
20. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-37.
21. Ritchie M, Tchistiakova L, Scott N. Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs. 2013;5(1):13-21.
22. Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35(4)
23. Parslow AC, et al. Antibody-drug conjugates for cancer therapy. Biomedicine. 2016;4(3):1-17.
24. Kovtun YV, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006;66(6):3214-21.
25. Kovtun YV, Goldmacher VS. Cell killing by antibody-drug conjugates. Cancer Lett. 2007;255(2):232-40.
26. Sammet B, Steinkuhler C, Sewald N. Antibody-drug conjugates in tumor therapy. Pharm Pat Anal. 2012;1(1):65-73.
27. Sigismund, S., et al., Endocytosis and signaling: cell logistics shape the eukaryotic cell plan. Physiol Rev, 2012. 92(1): p. 273-366.
28. Doherty GJ, McMahon HT. Mechanisms of endocytosis. Annu Rev Biochem. 2009;78:857-902.
29. Scita G, Di Fiore PP. The endocytic matrix. Nature. 2010;463(7280):464-73.
30. Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature. 2003;422(6927):37-44.
31. Ferguson SM, De Camilli P. Dynamin, a membrane-remodelling GTPase. Nat Rev Mol Cell Biol. 2012;13(2):75-88.
32. Stenmark H. Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol. 2009;10(8):513-25.
33. Russell MR, Nickerson DP, Odorizzi G. Molecular mechanisms of late endosome morphology, identity and sorting. Curr Opin Cell Biol. 2006;18(4):422-8.
34. White E, Mehnert JM, Chan CS. Autophagy, metabolism, and cancer. Clin Cancer Res. 2015;21(22):5037-46.
35. Luzio JP, Pryor PR, Bright NA. Lysosomes: fusion and function. Nat Rev Mol Cell Biol. 2007;8(8):622-32.
36. Lanzetti L, Di Fiore PP. Behind the scenes: Endo/Exocytosis in the Acquisition of Metastatic Traits. Cancer Res. 2017;77(8):1813-7.
37. Mellman I, Yarden Y. Endocytosis and cancer. Cold Spring Harb Perspect Biol. 2013;5(12):a016949.
38. Mosesson Y, Mills GB, Yarden Y. Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer. 2008;8(11):835-50.
39. Davidson, S.M. and M.G. Vander Heiden, Critical functions of the Lysosome in cancer biology. Annu Rev Pharmacol Toxicol, 2017. 57: p. 481-507.
40. Law CL, et al. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clin Cancer Res. 2004;10(23):7842-51.
41. Ingle GS, et al. High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate. Br J Haematol. 2008;140(1):46-58.
42. Gerber HP, et al. Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas. Blood. 2009;113(18):4352-61.
43. Pulczynski S, Boesen AM, Jensen OM. Antibody-induced modulation and intracellular transport of CD10 and CD19 antigens in human B-cell lines: an immunofluorescence and immunoelectron microscopy study. Blood. 1993;81(6):1549-57.
44. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41(1):98-107.
45. Ansell SM. Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells. Expert Opin Investig Drugs. 2011;20(1):99-105.
46. Younes A, Carbone A. CD30/CD30 ligand and CD40/CD40 ligand in malignant lymphoid disorders. Int J Biol Markers. 1999;14(3):135-43.
47. Sutherland MS, et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem. 2006;281(15):10540-7.
48. Okeley NM, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010;16(3):888-97.
49. Kuppers R. Molecular biology of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2009:491-6.
50. Masuda S, et al. CD30-targeting immunoconjugates and bystander effects. Nat Rev Clin Oncol. 2015;12(4)
51. Wang J, et al. Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer. Clin Pharmacol Ther. 2014;95(5):558-64.
52. Verma S, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783-91.
53. Slamon DJ, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707-12.
54. Yarden RI, Wilson MA, Chrysogelos SA. Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. J Cell Biochem Suppl. 2001;(Suppl 36):232-46.
55. Lewis Phillips GD, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280-90.
56. Austin CD, et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell. 2004;15(12):5268-82.
57. Diessner J, et al. Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1). Cell Death Dis. 2014;5:e1149.
58. Dreesen O, Brivanlou AH. Signaling pathways in cancer and embryonic stem cells. Stem Cell Rev. 2007;3(1):7-17.
59. Xie H, et al. Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. J Pharmacol Exp Ther. 2004;308(3):1073-82.
60. Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014;16(2):209.
61. Barok M, et al. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res. 2011;13(2):R46.
62. Pegram M, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 1999;18(13):2241-51.
63. Phillips GD, et al. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res. 2014;20(2):456-68.
64. Li JY, et al. A Biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell. 2016;29(1):117-29.
65. Kovtun YV, et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res. 2010;70(6):2528-37.
66. Spangler JB, et al. Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci U S A. 2010;107(30):13252-7.
67. Friedman LM, et al. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci U S A. 2005;102(6):1915-20.
68. Walter RB, et al. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood. 2012;119(26):6198-208.
69. Leith CP, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study Blood. 1997;89(9):3323-9.
70. Lehar SM, et al. Novel antibody-antibiotic conjugate eliminates intracellular S. Aureus. Nature. 2015;527(7578):323-8.
71. Polson AG, et al. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood. 2007;110(2):616-23.
72. Ojha R, Jha V, Singh SK. Gemcitabine and mitomycin induced autophagy regulates cancer stem cell pool in urothelial carcinoma cells. Biochim Biophys Acta. 2016;1863(2):347-59.
73. Vitale I, et al. Role of autophagy in the maintenance and function of cancer stem cells. Int J Dev Biol. 2015;59(1-3):95-108.
74. Lei Y, et al. Targeting autophagy in cancer stem cells as an anticancer therapy. Cancer Lett. 2017;393:33-9.
75. Saunders LR, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015;7(302):302ra136.
76. Mairhofer M, et al. Stomatin-like protein-1 interacts with stomatin and is targeted to late endosomes. J Biol Chem. 2009;284(42):29218-29.
77. Hamblett KJ, et al. SLC46A3 is required to transport Catabolites of noncleavable antibody Maytansine conjugates from the Lysosome to the cytoplasm. Cancer Res. 2015;75(24):5329-40.
78. Wang H, et al. Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells. Cancer Sci. 2017;108(7):1458 - 68.
79. Loganzo F, et al. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol Cancer Ther. 2015;14(4):952-63.
80. Loganzo F, Sung M, Gerber HP. Mechanisms of resistance to antibody-drug conjugates. Mol Cancer Ther. 2016;15(12):2825-34.
81. Yu SF, et al. A novel anti-CD22 Anthracycline-based antibody-drug conjugate (ADC) that overcomes resistance to Auristatin-based ADCs. Clin Cancer Res. 2015;21(14):3298-306.
82. Thorburn A, Thamm DH, Gustafson DL. Autophagy and cancer therapy. Mol Pharmacol. 2014;85(6):830-8.
83. Piao S, Amaravadi RK. Targeting the lysosome in cancer. Ann N Y Acad Sci. 2016;1371(1):45-54.
84. Amaravadi RK, et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res. 2011;17(4):654-66.
85. Parkinson-Lawrence EJ, et al. Immunochemical analysis of CD107a (LAMP-1). Cell Immunol. 2005;236(1-2):161-6.
86. Agarwal AK, et al. Role of tumor cell surface lysosome-associated membrane protein-1 (LAMP1) and its associated carbohydrates in lung metastasis. J Cancer Res Clin Oncol. 2015;141(9):1563-74.
87. Furuta K, et al. Expression of lysosome-associated membrane proteins in human colorectal neoplasms and inflammatory diseases. Am J Pathol. 2001;159(2):449-55.
88. Chan KT, et al. Overexpression of transferrin receptor CD71 and its tumorigenic properties in esophageal squamous cell carcinoma. Oncol Rep. 2014;31(3):1296-304.
89. Kallunki T, Olsen OD, Jaattela M. Cancer-associated lysosomal changes: friends or foes? Oncogene. 2013;32(16):1995-2004.
90. Apetoh L, et al. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? Ann Oncol. 2015;26(9):1813-23.